Actively Recruiting
High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes
Led by Finis Terrae University · Updated on 2026-03-16
36
Participants Needed
1
Research Sites
117 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
A recognized driver for cardiovascular complications of type 2 diabetes mellitus (T2DM) is impaired plasma glucose homeostasis as consequence of skeletal muscle insulin resistance. Insulin-mediated plasma glucose disposal in skeletal muscle comprises oxidative glucose disposal (cellular glucose uptake for oxidation) and non-oxidative glucose disposal (NOGD; cellular glucose uptake for storage as glycogen), both processes being impaired in T2DM patients. Excessive intrahepatic fat accumulation (particularly monounsaturated (MUFA) and saturated (SFA)) is commonly observed in T2DM patients and tightly associates with plasma glucose dysregulation. It has been hypothesized that skeletal muscle insulin resistance redistributes circulating glucose away from muscle which together with hyperinsulinemia promotes intrahepatic lipid accretion via de novo lipogenesis (DNL). As saturated lipids is the final product of DNL, improving skeletal muscle insulin sensitivity, next to enhance plasma glucose homeostasis, might lower intrahepatic lipid content particularly intrahepatic saturated lipids. Regular exercise is a cornerstone in the treatment of T2DM and to improve skeletal muscle insulin sensitivity. Interestingly, a conventional exercise program (aerobic-type combined with strength-type exercise) restores insulin-stimulated oxidative glucose disposal in T2DM patients to levels observed in age-matched normoglycemic subjects. Non-oxidative glucose disposal (NOGD), however, does not improve upon such conventional exercise programs. In this regard, for full restoration of compromised glucose disposal, it is pivotal to come up with effective training methods to target NOGD. High intensity interval training (HIIT) has the potential to expands the glycogen synthesis capacity in athletes by repetitive cycles of glycogen depletion/repletion, hence holds promise to improve NOGD in T2DM patients. Of note, HIIT also lowers the intrahepatic fat content in pre-diabetes individuals. Nevertheless, whether HIIT reduces the intrahepatic fat content and modifies its composition in T2DM patients is unknown. In this regard, it is hypothesized that HIIT expands the NOGD capacity in skeletal muscle of overweight/obese type 2 diabetes patients. By doing so, it is postulated that HIIT improves skeletal muscle insulin sensitivity and therefore benefits the 24 hours glycaemic profile in T2DM patients. In line, it is hypothesized that the HIIT-mediated improvements on NOGD and skeletal muscle insulin sensitivity coexist with the reduction of intrahepatic lipid content -particularly reduced saturated lipids- via lowering DNL.
CONDITIONS
Official Title
High Intensity Interval Training and Insulin Sensitivity in Type 2 Diabetes
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Participants are able to provide signed and dated written informed consent prior to any study specific procedures
- Aged 65 45 and 64 75 years
- BMI: 25-35 kg/m2
- Diagnosed as T2DM patients for at least 1 year and not longer than 5 years
- HbA1c 65 6.5% and 64 8.5%
- Fasting blood glucose <130 mg/dL
- Women are post-menopausal (>1 year cessation of menses)
- Being stable on medication use of metformin and/or sulfonylurea derivatives for the previous 3 months or more and other medication na�efve.
You will not qualify if you...
- Type 1 diabetes
- Patients with congestive heart failure and and/or severe renal and or liver insufficiency
- Contraindications for MRI/MRS examination
- Active diabetic foot
- Polyneuropathy or retinopathy
- Signs of active liver or kidney dysfunction
- BMI >35 kg/m2
- Exogeneous insulin therapy
- Use of antidiabetic medication other than metformin or sulfonylurea derivatives treatment within 3 months before screening
- Use of SGLT2 inhibitors
- Unstable body weight (variations >5kg in the last 3 months)
- Ongoing weight loss diet or use of weight loss agents
- Uncontrolled hypertension
- Engagement in regular exercise program or any other medical condition that will impede the safe performance of the experiments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Finis Terrae University
Santiago, Chile
Actively Recruiting
Research Team
R
Rodrigo Mancilla, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here